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lived physiological messenger. NO is synthesized by three different
gene-encoded NO synthases (NOS) in mammals: neuronal NOS
(nNOS or NOS-1), inducible NOS (iNOS or NOS-2) and endothelial
NOS (eNOS or NOS-3). NO regulates a variety of important phy-
siological responses, including vasodilation, respiration, cell mi-
gration, immune response and apoptosis. All these features are
relevant in cancer in which the key hallmarks are unlimited
replicative potential, insensitivity to growth-inhibitory signals,
evasion of apoptosis, cellular stress, sustained angiogenesis, inva-
siveness and metastatic potential. The present special issue en-
titled “Nitric oxide in cancer” derives from the IV International
Workshop on “Nitric oxide in cancer” held in the Institute of
Biomedicine of Sevilla (IBiS) (March 13–14, 2015). The program
included six sessions that were focused on “Nitric oxide, muta-
genesis, carcinogenesis, tumor promotion and tumor growth”,
“Nitric oxide regulation of cell death pathways”, “Nitric oxide:
proliferation and epithelial-mesenchymal transition”, “Regulation
of immune response by nitric oxide”, “Antitumoral activity of ni-
tric oxide-based releasing strategies: pre-clinical studies” and
“Antitumoral activity of nitric oxide-based releasing strategies:
clinical trials”. In addition, a keynote lecture entitled “Nitric oxide
and oxygen: Actions and interactions in health and disease” was
delivered by Sir. Salvador Moncada. The present thematic issue
“Nitric oxide in cancer” includes different original research
manuscripts and review articles written by participants in the
workshop and which were focused in all aspects discussed at the
meeting regarding the chemical reactivity of NO, its role in cell
proliferation/death and metabolism of tumor cells, as well as NO-
based antitumor activity or preventing the side effect of che-
motherapy during the treatment of patients with cancer.
NO has been shown to regulate different pathways involved in
the cell proliferation and death, as well as the epithelial-me-
senchymal transition of tumor cells [1,2]. In particular, STAT3 and
NF-κB are key transcription factors involved in tumor progression,
chemoresistance, and metastasis in cancer. Kaliyaperumal et al. [3]
demonstrated that S-nitrosylation of STAT3 and NF-κB has a
beneﬁcial effect during cisplatin and radiation-treated head and
neck cancer cells. Cell death signaling and proliferation are pro-
foundly altered by NO in tumor cells. In this sense, the intracellular
sustained generation of NO from NOS-3 induced cell death and
arrested cell proliferation, as well as altered cell metabolism and
redox status in hepatocellular carcinoma [4]. NO reacts withx.doi.org/10.1016/j.redox.2015.09.038
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é and Benjamin Bonavida.superoxide anion generated at the membrane level and re-
sponsible for tumor cell survival, with the further generation of
highly reactive species that promote apoptosis [5,6]. One of the
key features of tumor cells is the acquisition of resistance to
apoptosis. The S-nitrosylation of cell death receptors (TNF-R1,
CD95 and TRAIL-DR1) stimulates the extrinsic cell death signaling
[7]. In addition, the denitrosylating activity of cell death receptors
and cell proliferation arrest by Sorafenib, a tyrosine kinase in-
hibitor for the recommended treatment of patients with advanced
renal and liver cancer, promote the activation of downstream
apoptotic markers in hepatoblastoma cells [8]. NO donors such as
NOSH-Aspirin [9] and NOSH-Sulindac [10] have shown to exert
potent COX-1 and COX-2 inhibition, and reduced cell survival in
colon cancer cells. The susceptibility to induce NO production
during Bacillus Calmette-Guerin administration is relevant during
the treatment of patients with bladder cancer [11]. The effect of
NO on increased tumor blood ﬂow, cellular respiration, cell sig-
naling, and on the production of reactive oxygen and nitrogen
species (RONS) appear to be relevant for its activity as a radio-
sensitizer [12] and a photosensitizer [13]. In addition, the in-
creased diffusion of NO through the cytoplasm and plasma
membranes allows this signaling molecule to easily spread from
irradiated cells to bystander cells without the involvement of gap
junction intercellular communication. These NO-dependent effects
include the stimulation of genomic instability (GI) and the accu-
mulation of DNA errors in bystander cells without direct DNA
damage [14]. The effectiveness of tyrosine kinase inhibitors and
neutralizing antibodies against growth factors/receptors in pa-
tients with cancer are widely associated with increased hy-
pertension which has been postulated to be related to either direct
downregulation of NOS expression or the microvessel density
(rarefaction). In this sense, NO donors could be successfully used
not only for the treatment of developed angiogenesis-inhibitor-
induced hypertension but also for preventive effects [15].References
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